IRWD
Ironwood Pharmaceuticals Inc.
$1.92
+$0.42(+28.00%)
58
Overall
40
Value
91
Tech
44
Quality
Market Cap
$250.15M
Volume
4.36M
52W Range
$0.53 - $5.13
Target Price
$0.93
Order:
Income Statement
| Metric | Trend | Chart | 2015 Dec | 2016 Dec | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||||
| Total Revenue | $149.6M | $274.0M | $298.3M | $346.6M | $428.4M | $389.5M | $413.8M | $410.6M | $442.7M | $351.4M | ||
| Total Revenue | $149.6M | $109.0K | $298.3M | $346.6M | $428.4M | $389.5M | $413.8M | $410.6M | $442.7M | $351.4M | ||
| COST OF GOODS SOLD | ||||||||||||
| Cost of Revenue | $-12.0K | $-1.9M | $-19.1M | $-32.8M | $23.9M | $3.1M | $44.0K | -- | -- | -- | ||
| GROSS PROFIT | ||||||||||||
| Gross Profit | $131.9M | $271.7M | $278.9M | $313.6M | $404.5M | $386.4M | $413.8M | $410.6M | $442.7M | $351.4M | ||
| OPERATING EXPENSES | ||||||||||||
| Operating Expenses | $234.0M | $313.8M | $387.6M | $328.8M | $287.5M | $228.1M | $181.5M | $160.3M | $274.4M | $255.7M | ||
| Research & Development | $108.7M | $139.5M | $148.2M | $101.1M | $115.0M | $88.1M | $70.4M | $44.3M | $116.1M | $111.4M | ||
| Research Expense | $108.7M | $139.5M | $148.2M | $101.1M | $115.0M | $88.1M | $70.4M | $44.3M | $116.1M | $111.4M | ||
| Selling, General & Administrative | $125.2M | $173.3M | $233.1M | $219.7M | $172.4M | $140.0M | $111.1M | $116.0M | $158.3M | $144.3M | ||
| Selling & Marketing Expenses | $125.2M | $173.3M | $233.1M | $219.7M | -- | -- | -- | -- | -- | -- | ||
| General & Administrative Expenses | $-6.3M | $-11.6M | -- | -- | $172.4M | $140.0M | $111.1M | $116.0M | $158.3M | $144.3M | ||
| Salaries & Wages | $-25.5M | $-29.2M | $-33.8M | $-41.1M | -- | -- | $22.3M | $-1.6M | $-3.0M | $-3.4M | ||
| Depreciation & Amortization | $-11.6M | $981.0K | $6.2M | $8.1M | $5.6M | $2.3M | $1.5M | $1.4M | $1.2M | $1.2M | ||
| Depreciation & Amortization | $-11.6M | $981.0K | $6.2M | $8.1M | $5.6M | $2.3M | $1.5M | $1.4M | $1.2M | $1.2M | ||
| Amortization | -- | $981.0K | $6.2M | $8.1M | -- | $20.8M | $22.3M | $1.9M | $800.0K | $2.0M | ||
| Other Operating Expenses | $-17.6M | $-26.4M | $-24.1M | $-38.6M | $-51.7M | $-66.7M | $-83.2M | $-101.2M | $-85.4M | $-4.1M | ||
| OPERATING INCOME | ||||||||||||
| Operating income | $-102.1M | $-42.0M | $-108.7M | $-15.2M | $120.1M | $142.9M | $232.3M | $250.3M | $-945.4M | $93.1M | ||
| EBITDA | $-90.7M | $-15.8M | $-49.9M | $-127.0M | $120.7M | $141.9M | $257.2M | $263.3M | $-944.4M | $69.1M | ||
| NON-OPERATING ITEMS | ||||||||||||
| Interest Expense (Non-Operating) | $31.1M | $39.2M | $36.4M | $37.7M | $36.6M | $29.5M | $31.1M | $7.6M | $21.6M | -- | ||
| Intinc | $-40.6M | $-29.8M | $-39.6M | $-43.5M | -- | -- | -- | -- | -- | -- | ||
| Net Non-Operating Interest Income/Expense | $-30.7M | $-38.0M | $-34.3M | $-34.7M | $-36.6M | $-29.5M | $-31.1M | $-1.9M | $2.7M | -- | ||
| Gain on Sale of Securities | $-9.9M | $8.1M | $-3.3M | $-8.7M | $5.9M | $-4.6M | $-452.0K | $9.7M | $19.0M | $4.5M | ||
| Other Income/Expense | $9.9M | $1.7M | $-26.0M | $-22.3M | $24.6M | $4.6M | $452.0K | $182.0K | $-19.0M | $-5.1M | ||
| Other Special Charges | -- | -- | $-2.0M | $-67.2M | $-30.5M | $24.0K | $-31.6M | $2.1M | $-2.6M | $640.0K | ||
| SPECIAL ITEMS | ||||||||||||
| Restructring And Mn A Income | -- | -- | -- | $14.7M | $3.6M | $15.4M | $-854.0K | -- | $17.4M | $-109.0K | ||
| Special Income Charges | -- | -- | -- | $-166.5M | $-3.6M | $-15.4M | $854.0K | -- | $-17.4M | $109.0K | ||
| Impairment of Capital Assets | -- | -- | -- | $151.8M | -- | -- | -- | -- | -- | -- | ||
| PRE-TAX INCOME | ||||||||||||
| EBIT | $-111.6M | $-42.6M | $-80.6M | $-156.4M | $95.5M | $138.3M | $231.7M | $260.0M | $-948.1M | $65.2M | ||
| Pre-Tax Income | $-142.7M | $-81.7M | $-116.9M | $-194.1M | $58.9M | $108.9M | $200.7M | $252.4M | $-948.1M | $65.2M | ||
| INCOME TAX | ||||||||||||
| Tax Provision | -- | -- | $-153.9M | -- | $-1.9M | $2.7M | $-327.8M | $77.4M | $83.5M | $64.3M | ||
| NET INCOME | ||||||||||||
| Net Income | $-142.7M | $-81.7M | $-116.9M | $-282.4M | $21.5M | $106.2M | $528.4M | $175.1M | $-1.0B | $880.0K | ||
| Net Income (Continuing Operations) | $-142.7M | $-81.7M | $-116.9M | $-282.4M | $21.5M | $106.2M | $528.4M | $175.1M | $-1.0B | $880.0K | ||
| Net Income (Discontinued Operations) | $-142.7M | $-81.7M | $-116.9M | $-282.4M | $21.5M | $106.2M | $528.4M | $175.1M | $-1.0B | $880.0K | ||
| Net Income (Common Stockholders) | $-142.7M | $-81.7M | $-116.9M | $-282.4M | $8.1M | $136.9M | $528.4M | $175.1M | $-1.0B | $880.0K | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | -- | -- | -- | $64.4M | ||
| TOTALS | ||||||||||||
| Total Expenses | $234.0M | $311.9M | $368.5M | $296.1M | $311.4M | $231.2M | $181.6M | $160.3M | $274.4M | $255.7M | ||
| SHARE & EPS DATA | ||||||||||||
| Average Shares Outstanding | $142.2M | $144.9M | $149.0M | $152.6M | $156.0M | $159.4M | $162.2M | $154.4M | $155.4M | $159.1M | ||
| Average Shares Outstanding (Diluted) | $142.7M | $145.9M | $149.9M | $152.6M | -- | $160.7M | $164.4M | $186.3M | $155.4M | $160.1M | ||
| Shares Outstanding | $143.4M | $147.9M | $150.9M | $154.6M | $158.2M | $161.0M | $159.2M | $154.2M | $156.5M | $161.8M | ||
| Basic EPS | -- | -- | -- | -- | $0.14 | $1.34 | $3.26 | $1.13 | $-6.45 | $0.01 | ||
| Basic EPS (Continuing Operations) | -- | -- | -- | -- | $0.38 | $1.34 | $3.26 | $1.13 | $-6.45 | $0.01 | ||
| Diluted EPS | $-1 | $-0.56 | $-0.78 | $-1.85 | $0.38 | $1.32 | $3.21 | $0.96 | $-6.45 | $0.01 | ||
| Diluted EPS (Continuing Operations) | -- | -- | -- | -- | $0.38 | $1.32 | $3.21 | $0.96 | $-6.45 | $0.01 | ||
| OTHER METRICS | ||||||||||||
| Basic Discontinuous Operations | -- | -- | -- | -- | $-0.24 | -- | -- | -- | -- | -- | ||
| Diluted Discontinuous Operations | -- | -- | -- | $-0.58 | -- | -- | -- | -- | -- | -- | ||
| Earnings from equity interest | -- | -- | -- | -- | $-2.6M | -- | -- | -- | -- | -- | ||
| Earnings From Equity Interest Net Of Tax | -- | -- | -- | -- | $-2.6M | -- | -- | -- | -- | -- | ||
| Gain On Sale Of P P E | -- | $204.0K | $-694.0K | $1.9M | -- | -- | -- | -- | -- | -- | ||
| Gains Loss On Disposal Of Discontinued Operations | -- | -- | -- | $-88.2M | -- | -- | -- | -- | -- | -- | ||
| Interest Expense Operating | -- | -- | -- | -- | -- | $7.2M | $7.2M | -- | -- | -- | ||
| Minority Interests | -- | -- | -- | -- | -- | -- | -- | -- | $29.3M | -- | ||
| Net Income Discontinuous Operations | -- | -- | -- | $-88.2M | $-37.4M | -- | -- | -- | -- | -- | ||
| Other Gain Loss From Disposition Of Discontinued Operations | -- | -- | -- | -- | $-37.4M | -- | -- | -- | -- | -- | ||
| Other Gand A | $-6.3M | $-11.6M | -- | -- | $172.4M | $140.0M | $111.1M | $116.0M | $158.3M | $144.3M | ||
| Other Impairment Of Capital Assets | -- | -- | -- | $-151.8M | -- | -- | -- | -- | -- | -- | ||
| Rent And Landing Fees | $-6.3M | $-11.6M | -- | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $125.2M | $173.3M | $233.1M | $219.7M | -- | -- | -- | -- | -- | -- | ||
| Restruct | -- | -- | -- | $14.7M | $3.6M | $15.4M | $-854.0K | -- | $17.4M | $-109.0K | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | IRWD | $1.92 | +28.0% | 4.36M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |
Get Ironwood Pharmaceuticals Inc. Data in Excel
Stream real-time data directly to your spreadsheets
BUY NOW